A redox probe screens MTHFD1 as a determinant of gemcitabine chemoresistance in cholangiocarcinoma

• Main Authors: Ruogu Pan, Zhiqing Yuan, Yingbin Liu, Xuxu Sun, Guiyang Wang, Xiaopen Wang, Junwen Qu, Jian Wang, Jie Yang, Yuzheng Zhao, Yi Yang, Kewei Li
• Format: Article
• Language: English
• Published: Nature Publishing Group 2021-05-01
• Series: Cell Death Discovery
• Online Access: https://doi.org/10.1038/s41420-021-00476-2

Abstract Cholangiocarcinoma (CCA) is a type of solid tumor derived from the bile duct epithelium that features universal gemcitabine resistance. Here, we utilized a gene-encoded ROS biosensor probe (HyPer3 probe) to sort subpopulations with different redox statuses from CCA cells. The isolated HyPer-low subpopulation CCA cells, which exhibited relatively lower cellular ROS levels, exhibited higher chemoresistance to gemcitabine than HyPer-high subpopulation CCA cells in vitro and in vivo. Mechanistically, increased expression of MTHFD1 was found in HyPer-low cells. Knocking down MTHFD1 in HyPer-low cells enhanced cellular ROS and restored sensitivity to gemcitabine. Furthermore, the MTHFD1 inhibitor antifolate compound methotrexate (MTX) increased cellular ROS, and combining gemcitabine with MTX effectively suppressed cholangiocarcinoma cell growth. In summary, the MTHFD1 level mediated the heterogeneous cellular redox status in CCA, which resulted in chemoresistance to gemcitabine. Our data suggest a novel strategy for CCA chemotherapy.